<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To investigate the influence of donor type (human leukocyte antigen [HLA] -identical sibling donor versus HLA-A-, HLA-B-, HLA-Cw-, HLA-DRB1-, and HLA-DQB1-identical unrelated donors, or so-called 10/10) on the outcome of patients who underwent allogeneic stem-cell transplantation (alloSCT), adjusting for other prognostic factors, in patients with standard-risk <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Between March 2000 and January 2003, we prospectively investigated the outcome of 236 consecutive patients with standard-risk <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> from 12 French centers </plain></SENT>
<SENT sid="2" pm="."><plain>Fifty-five patients underwent alloSCT from an unrelated HLA-identical donor at the allelic level, whereas 181 patients received an alloSCT from an HLA-identical sibling </plain></SENT>
<SENT sid="3" pm="."><plain>Diagnoses included <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (n = 175), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 43), and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; n = 18) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received unmodified marrow graft following myeloablative conditioning with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and total-body irradiation </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and short-course <z:chebi fb="0" ids="44185">methotrexate</z:chebi> in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In multivariable analysis, overall survival and transplantation-related mortality were adversely influenced by recipient cytomegalovirus (CMV) -positive serology, age of donor older than 37 years, and the occurrence of <z:hpo ids='HP_0011009'>acute</z:hpo> grade &gt; or = II GVHD </plain></SENT>
<SENT sid="7" pm="."><plain>Event-free survival rates were lower for patients with recipient CMV-positive serology </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> grades II to IV GVHD rates were higher for patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) </plain></SENT>
<SENT sid="9" pm="."><plain>No factor was found to influence either relapse or <z:hpo ids='HP_0011009'>acute</z:hpo> grades III to IV GVHD </plain></SENT>
<SENT sid="10" pm="."><plain>The effect of donor type was nonsignificant for <z:hpo ids='HP_0000001'>all</z:hpo> criteria </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: In patients with standard-risk <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, transplantation from unrelated HLA-allellically matched donors led to outcomes similar to those from HLA-identical sibling donors </plain></SENT>
</text></document>